Deal or Case news
NautaDutilh has assisted clinical-stage genetic medicines company Vico Therapeutics on its EUR 54 million Series B financing round.

The funding will be used for the development of therapies for severe neurological diseases, in particular the Phase 1/2a trial of its lead product candidate VO659 which is being developed for multiple polyglutamine disorders, spinocerebellar ataxia type 3, type 1 and Huntington's disease.

It has been a great pleasure to support Vico in reaching this important milestone, which will enable them to accelerate their efforts to advance their VO659 clinical-stage program for certain rare devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available.
Philippe Remels

The financing was led by new investor Ackermans & van Haaren (AvH) and by existing investors Droia Ventures, EQT Life Sciences and Kurma Partners, with participation of existing investors Polaris Partners, Pureos Bioventures and Eurazeo.

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.